Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Metadata
Title
A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis
Author
Dr Jean-Pierre Devogelaer
Publication date
01-08-1998
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 2/1998
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-199819020-00005

Other articles of this Issue 2/1998

Drug Safety 2/1998 Go to the issue

Review Article

Comparative Tolerability Profile of Hypertensive Crisis Treatments

Review Article

Adverse Haematological Effects of Ticlopidine

Review Article

Comparative Tolerability of Drug Therapies Used to Treat Incontinence and Enuresis

Review Article

Treatment of Nausea and Vomiting in Pregnancy

Current Opinion

Does Influenza Vaccination Exacerbate Asthma?